Maxcyte (MXCT) Net Margin (2020 - 2026)

Maxcyte (MXCT) has 7 years of Net Margin data on file, last reported at 105.53% in Q1 2026.

• On a quarterly basis, Net Margin fell 677.0% year-over-year to 105.53% in Q1 2026; TTM through Mar 2026 was 259.62%, a 11831.0% decrease from a year earlier, with the FY2025 full-year figure at 168.24%, down 2207.0% from the prior year.
• Net Margin for Q1 2026 stood at 105.53%, down from 201.22% in the prior quarter.
• Over the last five years, Net Margin for MXCT reached as high as 201.22% in Q4 2025 and fell as low as 369.04% in Q4 2022.
• Historically, Net Margin has averaged 155.89% across 5 years, with a median of 170.59% in 2024.
• Across the five-year window, Net Margin slumped 30466 bps in 2022 and jumped 37623 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 369.04% in 2022, then jumped by 95 bps to 19.88% in 2023, then slumped by 780 bps to 175.01% in 2024, then surged by 215 bps to 201.22% in 2025, then slumped by 152 bps to 105.53% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 105.53% in Q1 2026, 201.22% in Q4 2025, and 181.81% in Q3 2025.